Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
BioAmber Inc. (BIOA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/26/2018 |
8-K
| Asset disposition |
| 08/14/2018 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"BioAmber Provides Update on Liquidation Process Montreal, Canada, August 9, 2018. BioAmber Inc. announces that following a court order issued on July 31, 2018, the company, along with its monitor, PricewaterhouseCoopers , has initiated a liquidation process pursuant to which offers will be solicited from liquidators and/or strategic buyers to proceed with the liquidation of the company's assets or a recapitalization transaction with the goal of realizing the greatest value on behalf of the company's creditors. Binding offers from the liquidators or strategic buyers must be received by 9 a.m. on August 21st , 2018, and if acceptable offers are received, the company will seek to obtain court approval of the retained offer on August 28 th , 2018 and close the transaction on August 31st , 2018..." |
|
| 08/01/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/20/2018 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"BioAmber Receives Favourable Court Ruling and Approval for DIP Financing Montreal, Canada, June 18, 2018. BioAmber Inc. announced today that it has received formal Quebec court approval for debtor-in-possession financing. This funding will enable the execution of the Sales and Investor Solicitation Process that commenced on June 1, 2018, as well as the continued operations of the Sarnia manufacturing facility. Highlights of the court ruling include: • For the SISP, non-binding letters of intent are now due by June 29, 2018, with binding term sheets being due by July 31, 2018; • The stay of proceedings against the petitioners has been extended by the court to July 31, 2018, consistent with the timing of the SISP; • A CAN$3 million DIP financing, provided by Maynbridge Capital, will be disb..." |
|
| 05/08/2018 |
8-K
| Bankruptcy or Receivership, Financial Statements and Exhibits |
| 02/16/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 02/15/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 02/08/2018 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement, by and between BioAmber Inc. and H.C. Wainwright & Co., LLC",
"Form of Series A Warrant to Purchase Common Stock of BioAmber Inc",
"Form of Pre-Funded Warrant to Purchase Common Stock of BioAmber Inc",
"Opinion of Goodwin Procter LLP",
"BIOAMBER INC. ANNOUNCES PRICING OF US$10 MILLION UNDERWRITTEN PUBLIC OFFERING Montreal, Canada, February 6, 2018. BioAmber Inc. announced today that it has priced an underwritten public offering of an aggregate of 40 million Series A units , with each Series A unit consisting of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock, and each Series B unit consisting of one pre-funded warrant to purchase one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock, at a price to the public of US$0.25 per Series A unit and US$0.24 per Series B unit. The Series A warrants have an exercise price of US$0.25 and a ..." |
|
| 02/05/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Waiver to Loan Agreement, among BioAmber Sarnia Inc., Comerica Bank and the other parties thereto",
"BIOAMBER INC. ANNOUNCES UNDERWRITTEN OFFERING Montreal, Canada, February 5, 2018. BioAmber Inc. announced today that it has commenced an underwritten public offering of its Series A units, with each Series A unit consisting of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock. The Company is also offering Series B units, in lieu of Series A units, to those purchasers whose purchase of additional Series A units in the offering would result in the purchaser beneficially owning more than 4.99% of the Company's outstanding common stock following the offering, if they so choose. The Series B units will consist of pre-funded warrants to purchase one share of common stock, Series A warrants to purc..." |
|
| 01/26/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 11/08/2017 |
8-K
| Quarterly results |
| 10/24/2017 |
8-K
| Quarterly results |
| 09/14/2017 |
8-K
| Quarterly results |
| 09/13/2017 |
8-K
| Quarterly results |
| 08/11/2017 |
8-K
| Quarterly results |
| 08/03/2017 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...|
Docs:
|
"Share Purchase Agreement, by and among BioAmber Inc., BioAmber Sarnia Inc. and Mitsui & Co., Ltd",
"Indemnity Agreement, by and among BioAmber Inc., BioAmber Sarnia Inc. and Mitsui & Co., Ltd",
"Security Agreement, by and among BioAmber Inc., BioAmber Sarnia Inc. and Mitsui & Co., Ltd",
"Sales of bio-succinic acid were a quarterly record of $4.1m, a 64% increase over Q2-2016 and 94% over Q1-2017 revenues. - 9 new customers began buying bio-succinic acid in the second quarter. That brings the total of new customers for the first half of the year to 16. - Launch of BIO-SA pharmaceutical grade. - Operating expenses in Q2 -2017 were 29% lower than in Q1-2017. - Successfully negotiated buyback of Mitsui equity stake in Sarnia. Q2 – 2017 Financial Results Revenues for the quarter ended June 30, 2017 were $4.1 million, an increase of 64% over the previous quarter, mainly driven by growth in succinic acid volume sold, slightly offset by a decrease in average selling price. Cost of goods sold increased from $3.5 million for the three months ended June 30, 2016 to $5.7 million for t..." |
|
| 05/15/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/09/2017 |
8-K
| Form 8-K - Current report |
| 05/03/2017 |
8-K
| Form 8-K - Current report |
| 03/31/2017 |
8-K
| Form 8-K - Current report |
| 03/16/2017 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 02/21/2017 |
8-K
| Form 8-K - Current report |
| 01/30/2017 |
8-K
| Form 8-K - Current report |
| 01/27/2017 |
8-K
| Form 8-K - Current report |
| 01/23/2017 |
8-K
| Form 8-K - Current report |
| 12/29/2016 |
8-K
| Form 8-K - Current report |
| 12/23/2016 |
8-K
| Form 8-K - Current report |
| 09/14/2016 |
8-K
| Form 8-K - Current report |
| 08/09/2016 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 08/09/2016 |
8-K
| Form 8-K - Current report |
| 05/20/2016 |
8-K
| Form 8-K - Current report |
| 05/03/2016 |
8-K
| Form 8-K - Current report |
| 04/26/2016 |
8-K
| Form 8-K - Current report |
| 03/14/2016 |
8-K
| Form 8-K - Current report |
|
|
|